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HUMAN recombinant lipocortins (LCT) 1 and 5 have been
expressed in a yeast secretion vector and purified by ion
exchange chromatography. The action of the proteins has
been investigated in two models of experimental acute
inflammation in the rat: carrageenin induced paw oedema
and zymosan induced pleurisy. The effects of the proteins
on PGE2 release in vitro by rat macrophages stimulated
with zymosan and on rat neutrophil chemotaxis induced
by FMLP have also been assessed. LCT-1 significantly
inhibited both paw swelling in carrageenin oedema and
leukocyte migration in zymosan pleurisy. Moreover it
showed a dose dependent, inhibitory effect on PGE2
release. Neutrophil chemotaxis was only weakly affected
by LCT-1. Conversely LCT-5 did not reduce carrageenin
oedema and slightly inhibited PGE2 release, but showed
profound, dose dependent inhibitory activity on leukocyte
migration in zymosan pleurisy and on neutrophil
chemotaxis. These data suggest that LCT-1 acts mainly
by interfering with arachidonic acid metabolism via the
inhibition of phospholipase A.. The anti-inflammatory
activity of LCT-5, at variance with LCT-1, may be due to
a direct effect on cell motility in addition to the
interference with arachidonic acid metabolism.
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Introduction
Glucocorticoids are drugs endowed with a potent
anti-inflammatory effect, although the mechanism
of action is not completely understood. It has been
proposed that they inhibit phospholipase a2 (PLA2)
activity and thus prevent eicosanoid formation. The
inhibitory effect of glucocorticoids on PLA2 appears
to be mediated by inducible inhibitory proteins
called lipocortins (tCTs). After the cloning and
identification of the gene of lipocortin 1 (LCT-1) it
has been shown that they belong to a larger family
of proteins (annexins) with calcium and phospholi-
pid binding properties, whose precise biological
role is not yet clear.
2 In vivo anti-inflammatory
activity has been reported in experimental infl-
ammation for recombinant LCT-13 and for a
purified 36 kDa protein immunologically related to
lipocortin 5 (LCT-5).
4 Recently, by aligning the
sequences of LCT-5 and uteroglobin (another
anti-PLA2 protein) a nine aminoacid conservative
region has been identified. The peptide deriving
from this region of LCT-5 (amino acids 204-212)
has shown anti-inflammatory activity both in vitro
and in vivo suggesting that it could represent the
active site of the anti-inflammatory effect of LCT-5.
In this paper the anti-inflammatory mechanism of
LCT-1 and LCT-5 has been investigated both in
vitro and in vivo. The results confirm that the two
(C) 1993 Rapid Communications of Oxford Ltd
proteins possess anti-inflammatory activity and
suggest that they act differently in the control of
experimental inflammation.
Materials and Methods
Expression and purification of the proteins: Human
LCT-1 and LCT-5 have been obtained as
recombinant proteins by using a yeast expression/
secretion.system. The published cDNAs6’7 for both
proteins have been subcloned into the Saccharomyces
cerevisiae secretion vector YEpsec 1 previously
described. Yeast cells transformed with the
recombinant plasmids secrete the heterologous
proteins into the culture medium containing
galactose as inducer of expression. The proteins
secreted in the yeast culture medium were purified
by ion exchange chromatography. The medium
containing LCT-1 was first applied to a pre-
equilibrated 20 2.5 cm column of DEAE cellu-
lose (DE-52 Whatman, Maidstone, UK) in 25 mM
Tris buffer pH7.7 and thoroughly washed at
1 ml/min with the same buffer. In these conditions
the LCT-1 was recovered in the flow-through
fractions that were pooled, dialysed and lyophilized.
These samples were resuspended in 25 mM
diethanolamine buffer pH 8.8 and applied to a
8 x 1 cm column of Q-Sepharose (Pharmacia,
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Uppsala, Sweden) and run at 1.1 ml/min in the same
buffer. The fractions containing the protein
(flow-through) were collected, dialysed against
1 x 100 vol of 20 mM ammonium carbonate buffer
pH 8.0 and lyophilized. LCT-5 was purified by
applying the yeast medium to a QAE-Zprep 60 disk
(Cuno, Meriden, CT, USA) previously equilibrated
in 250 mM Tris buffer pH 7.0. After washing with
25 mM Tris pH 7.0, the elutio.n of the protein
was performed by applying a gradient of NaC1
(0.1-0.5 M) in the same buffer (100 ml). LCT-5
eluted in 0.2M NaC1 and was dialysed and
lyophilized as above. To use as negative control
in inflammation experiments (see below) a sham
protein (SHAM) was prepared using a yeast
strain transformed with a plasmid lacking the
LCT cDNA and purified as described for LCT-1.
Western blotting analysis: Western blots were performed
on the proteins separated in 10% polyacrylamide
gels and electroblotted to nitrocellulose membranes
as described previously. Immunodetection was
carried out using specific polyclonal antibodies
raised against the amino terminus of the pro-
teins. The amino termini (amino acids 15-31,
ENEEQEYVQTVKSSKGG, for LCT-1 and ami-
no acids 1-11, MAQVLRGTVTD, for LCT-5)
were synthesized with an Applied Biosystems 430 A
peptide synthesizer. The peptides (1 mg/ml in PBS)
were cross-linked to 400#g keyhole limpet
haemocyanin (Calbiochem. San Diego, CA, USA)
by incubation in 0.5 ml of 20 mM glutaraldehyde at
room temperature for 30 min. Antibodies were
raised in New Zealand male rabbits by subcutan-
eous injection of the crosslinked peptides (1 mg in
complete Freund’s adjuvant). Booster injections of
the cross-linked peptides in incomplete Freund’s
adjuvant were given 7, 14, 24 and 60 days later and
rabbits bled 2 weeks after the last injection.
Additional Western blots were also performed with
polyclonal antibodies raised against the entire
proteins (kindly supplied by Dr J. L. Browning,
Biogen, Cambridge, MA, USA).
Animals: Male Wistar rats (200-250 g body weight)
were purchased from Charles River, Calco, Italy and
housed for a week before experiments.
PGEe release by rat peritoneal macrophages: Macrophages
were collected as described previously, Briefly, rat
peritoneal cavities were washed with 20 ml
PBS + 5 U/ml heparin (Roche, Basel, Switzerland)
and cells plated at I x 106 per well in cluster 24-well
plates (Costar, Cambridge, MA, USA), in RPMI
1640 medium (Gibco, Paisley, UK) with 20% foetal
calf serum. After 3 h incubation at 37C in 5% COg,
non-adherent cells were removed by washing with
serum-free medium and the adherent macrophages
incubated with the proteins for 30min. After
stimulation with 200 g/ml opsonized zymosan
(Sigma, St Louis, MO, USA) for 60 min, in a final
volume of 0.5 ml of serum free medium, super-
natants were collected and PGE2 concentration
assessed by a specific radioimmunoassay (NEN-
DuPont, Dreieich, Germany). Cell viability was
always greater than 98% as measured by the trypan
blue exclusion test.
Polymorphonuclear leukocyte chemotaxis: The chemotaxis
assay was performed according to Harvarth et al.10
Polymorphonuclear leukocytes (PMN) were col-
lected by rat peritoneal washing (20 ml PBS +
5 U/ml heparin) 4 h after the i.p. injection of 10 ml
of 5% thioglycollate (Difco, Detroit, MI, USA).
The final suspension contained 1.5 106 cells/ml in
the following buffer: 145 mM NaC1, 5 mM KC1,
1 mM MgSO4, 10 mM HEPES, 10 mM glucose,
1 mM CaCl2, pH 7.4. Cell suspension (0.45 ml,
6.75 10 PMN) was incubated with increased
concentrations of the proteins (50 #1) at 37C for
20min. An aliquot of the suspension was
transferred to a 48-well Boyden chemotaxis
chamber (Neuro Probe Inc., Bethesda, MD, USA)
fitted with 3m polycarbonate membranes (Nu-
cleopore, Pleasanton, CA, USA). The migration
was induced by 1/,M formyl-methionyl-leucyl-
phenylalanine (FMLP, Sigma, St Louis, MO, USA)
for 45 min at 37C in 5% CO2. The migrating cells
were stained with Diff-Quik reagent (Merz-Dade
AG, Dudingen, Switzerland) and counted with a
light microscope. Ten separated fields of each well
were counted at 100.
Carrageenin oedema: The oedema was induced by the
subplantar injection of 0.1 ml of 1% carrageenin
(Sigma, St Louis, MO, USA) in 0.9% NaC1 into the
right hindpaw of rats, as described previously, The
proteins were administered i.v. (1 ml/kg) immedi-
ately before carrageenin injection (time 0). Control
animals received the vehicle (saline). The paw
volume was measured in a double blind manner
with a water plethysmometer (Basile, Comerio,
Italy) at time 0 and every 60 min up to 5 h.
Zymosan pleurisy: The pleurisy was induced as
described by Perretti et al.
11 Briefly, rats were
injected intrapleurally with 0.2 ml of 2 mg/ml
zymosan in 0.9% NaC1 and killed by CO2 inhalation
4 h later. The pleural cavities were washed with
1 ml of PBS + 5 U/ml heparin, the fluids collected
and total and differential count of cells performed
by using Turk’s staining and a Neubauer
haematocytometer. The proteins were administered
i.v. (1 ml/kg) 30 min before zymosan injection. The
doses of the proteins used in the oedema and
pleurisy experiments were established on the basis
of preliminary experiments. Control animals re-
ceived the vehicle (saline).
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Statistical analysis: Statistical significance on original
values was assessed by one-tail Student’s t-test for
unpaired samples with p < 0.05 regarded as
significant.
Results
Purity and identification of the proteins: Figure 1 shows
representative SDS-PAGE gels of LCT-5 (lane 1)
and LCT-1 (lane 2) after purification. Purity was
> 90% for LCT-1 and > 80% for LCT-5. Figure 1
also shows that the proteins were recognized in
Western blots by polyclonal antibodies raised
against the entire molecules (lane 3 for LCT-5 and
lane 4 for LCT-1) as well as by antibodies raised
against the amino termini (lane 5 for LCT-5 and
lane 6 for LCT-1).
FIG. 1. SDS-PAGE gels of human recombinant LCT-5 (lane and LCT-1
(lane 2) expressed in S. cerevisiae. Western blot analysis of LCT-5 (lane
3) and LCT-1 (lane 4) performed with antibodies raised against the whole
molecules. Western blot analysis of LCT-5 (lane 5) and LCT-1 (lane 6)
performed with antibodies raised against the amino termini.
Efect of lipocortins on PCEe release" LCT-1 reduced in
a dose dependent manner the release of PGE2 from
activated macrophages with a maximum inhibition
of about 70% at 1 ng/ml. LCT-5 showed a weaker
effect with a peak inhibition of about 40% at
1 ng/ml. The sham protein preparation had no
significant inhibitory effect on PGE2 release (Table
1).
Effect of lipocortins on PMN chemotaxis: The chemotaxis
of rat PMN was dose dependently reduced by
LCT-5 with significant inhibition at 10 and
100 ng/ml (21.8% and 41.7% respectively). LCT-1
caused a 30% inhibition at 1 ng/ml which did not
increase at higher concentrations. PMN chemotaxis
was not inhibited by the sham protein (Table 2).
Eect of lipocortins on carrageenin oedema: The i.v.
administration of LCT-1 (1 mg/kg) resulted in a
profound and long-lasting reduction of the paw
swelling induced by the phlogogen compound. The
inhibition was significant at 2, 3 and 4 h after
carrageenin injection. In contrast, the same i.v. dose
of LCT-5 was completely ineffective in reducing
carrageenin oedema. As a rhatter of fact, the first
hour oedema was substantially increased by LCT-5
(Fig. 2).
Effect of lipocortins on ymosan pleurisy: The i.v.
administration of both LCT-1 and LCT-5 (1 mg/kg)
significantly inhibited the migration of PMN and
mononuclear (MN) cells induced by the intrapleural
injection of zymosan. LCT-5 was more eective
Table 1. Effect of LCT-1 and LCT-5 on PGE2 release from zymosan stimulated rat
peritoneal macrophages (n)
% Inhibition
Protein
concentration Sham LCT- LCT-5
0.01 ng/ml 7.7 _+ 4.5 (3)
0.1 ng/ml 16.4 -t- 10.5 (3)
1.0 ng/ml 11.7+ 7.6 (3)
6.4 +_ 5.4 (3) 15.2-t- 5.7 (6)
26.0 +_ 9.0* (3) 11.6 4- 10.0 (6)
64.7 + 8.8** (6) 37.3 4.8** (6)
Results are means _+ S.E. of % inhibition vs. control values (PGE2 release from
macrophages in absence of proteins" 1.8+0.013 ng/ml, n=4). *p<0.05;
**p < 0.01.
Table 2. Effect of LCT-1 and LCT-5 on chemotaxis of rat PMN stimulated with
FMLP (n)
% Inhibition
Protein
concentration Sham LCT- LCT-5
0.1 ng/ml ND 0 (3) 0 (4)
ng/ml 0 (3) 29.4 -t- 9.0** (9) 3.0-t- 2.2 (4)
10 ng/ml 0 (3) 24.5 4- 8.7 (9) 21.8 4- 4.5** (13)
100 ng/ml 0 (3) 26.8 -t- 10.1 (9) 41.7 4- 4.9** (13)
Results are means 4- S.E. of % inhibition vs. control values (migrated cells/well
in absence of proteins" 347.9 4- 85.5, n 15). **p < 0.01, ND not done.
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FIG. 2. Effect of LCT-1 and LCT-5 on carrageenin induced paw oedema.
Proteins were administered i.v. at time O. Results are means-t-S.E.
(n 10 for saline and LCT-5 treated groups, n 5 for LCT-1 treated
group). 0, saline; r-I, LCTol mg/kg i.v.; /, LCT-5 mg/kg i.v.
**p < 0.01 vs. saline treated animals.
than LCT-1 in the inhibition of the migration of
either type of cells (PMN --66%, MN --87% for
LCT-5; PMN --37%, MN --67% for LCT-1).
Leukocyte migration was not significantly modified
by i.v. injection of the sham protein (Fig. 3).
Discussion
The present results indicate that LCT-1 and LCT-5
possess anti-inflammatory activity with some
differences. Both proteins inhibited leukocyte
migration in vivo during zymosan induced pleurisy
whereas only LCT-5 caused a dose dependent
inhibition ofPMN chemotaxis in vitro. On the other
hand, LCT-5 was less potent than LCT-1 in
reducing PGE2 release from activated macrophages
and was ineffective in reducing carrageenin induced
paw oedema where LCT-1 gave a significant and
long-lasting inhibition.
The anti-inflammatory profile of LCT-1 is
consistent with inhibition of PLA2 activity. In fact
5O
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FIG. 3. Effect of LCT-1 and LCT-5 on the migration of polymorphonuclear
(PMN) and mononuclear (MN) leukocytes in zymosan pleurisy at 4 h.
Proteins were administered i.v. 30 min before intrapleural injection of
zymosan. Results are means _+ S.E. (n 10 for saline and LCT-5 treated
groups, n 5 for sham and LCT-1 treated groups). I-I, PMN; I, MN.
**p < 0.01 ***p < 0.001 vs. saline treated animals.
the preferential effect on leukocyte migration in vivo
is likely due to the down-regulation of the synthesis
of chemotactic mediators like LTB4 and PAF-
acether. LCT-1 is indeed capable, like glucocorti-
coids, of impairing the formation of all lipid
metabolites originating from PLA2 activation.
Moreover, LCT-1 and dexamethasone have been
shown to reduce PMN migration induced in vivo by
interleukin-1 (IL-1),
12 which is known to activate
PLA2 .13 These data support a regulatory feedback
mechanism by LCT-1 and IL-1 on PLA2 activity,
as suggested previously.
14 Recently, the presence of
saturable binding sites for LCT-1 has been
demonstrated on peripheral blood monocytes and
neutrophil/s, but not on lymphocytes. The low
LCT-1 concentration in plasma results in low
receptor occupancy,
is It is then conceivable that i.v.
administered LCT-1 binds to receptors on blood
leukocytes reducing the cell capability to migrate
into the inflammatory sites. At variance with blood
cells, elicited leukocytes present fewer binding sites
for LCT-1.16 This could explain why the inhibitory
effect of LCT-1 on chemotaxis in vitro reached a
plateau at 1 ng/ml and did not increase with
concentration. The anti-inflammatory activity of
LCT-1 in the carrageenin oedema confirms previous
data obtained with a human recombinant protein
expressed in Escherichia coli
3 whereas other authors
did not observe any inhibitory effect with a protein
purified from human placenta.v This discrepancy is
likely due to the different biological activity of the
proteins, given the extreme sensitivity of LCT-1 to
denaturation and the structural heterogeneity of the
various preparations.
18
The anti-inflammatory profile of LCT-5 suggests
that this protein directly affects cell motility in
addition to the interference with arachidonic acid
metabolism. The carrageenin induced oedema was
not inhibited by LCT-5, rather the paw swelling at
the first hour was increased by the protein, an effect
possibly due to contaminants in the preparation.
The lack of inhibition of carrageenin oedema by
LCT-5 can be ascribed to the relatively weak effect
of the protein on PGE2 release, since prostaglandins
are important mediators in this model of
inflammation.
9 Since LCT-5 was administered
intravenously, it is possible that, in the paw, it did
not reach the concentration necessary to inhibit
eicosanoid release. This view is supported by the
fact that a peptide from LCT-5, injected directly in
the paw, was able to inhibit the carrageenin
oedema. It is of interest that a 36 kDa protein,
related to LCT-5, was able to inhibit PMN
migration and eicosanoid formation in a model of
murine inflammation. This protein also inhibited
PMN chemotaxis in vitro.
4 The decreased eicosanoid
formation in vivo could have been a consequence of
the reduced cell migration. The anti-inflammatory
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effect of LCT-5 could be related to the inhibition
of protein kinase C (PKC) activity.
2 It has been
suggested that PKC activation in leukocytes leads
to cellular responses like lysosomal enzyme release,
arachidonate release and superoxide formation.
21 In
agreement with this hypothesis it has been shown
recently that PKC inhibition results in anti-
inflammatory activity.
22 Alternatively or addition-
ally, the inhibitory effect of LCT-5 on cell motility
could be due to the property of the protein to
tightly bind to negatively charged phospholipids
present on activated cell surfaces. It has been shown
that LCT-5 binds strongly to membranes of
activated macrophages, but not of resting cells.
23
This is supported by the recent observation that
peripheral blood leukocytes have very few binding
sites for LCT-5 (N. Goulding, personal communi-
cation).
Whatever the mechanism of action, which
deserves further study, LCT-1 and LCT-5 possess
anti-inflammatory activity with some conceivable
differences. This observation is very interesting in
the light of recent data from the authors’ laboratory
on the expression of lipocortins brought about by
glucocorticoids. The authors have shown that
dexamethasone induces the release of LCT-1 and
LCT-5, but not of LCT-2, from differentiated U-937
cells. Therefore it can be suggested that glucocorti-
colds could control the different facets of the
inflammatory process through the release of
lipocortins endowed with different actions.
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